In an adult (including older adults) needing a sleep aid with minimal next‑day sedation, how does low‑dose doxepin compare to trazodone in terms of efficacy, side‑effects, and safety?

Low-Dose Doxepin vs. Trazodone for Insomnia with Minimal Next-Day Sedation

Low-dose doxepin (3-6 mg) is the superior choice over trazodone for adults needing a sleep aid with minimal next-day sedation, based on stronger evidence for efficacy in sleep maintenance and a more favorable side effect profile regarding residual daytime effects. 1

Guideline Recommendations

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline provides clear, divergent recommendations for these two agents 1:

• Doxepin (3-6 mg): AASM suggests clinicians use doxepin as treatment for sleep maintenance insomnia (WEAK recommendation) 1
• Trazodone (50 mg): AASM suggests clinicians not use trazodone as treatment for sleep onset or sleep maintenance insomnia (WEAK recommendation) 1

The American College of Physicians (2016) found low-to-moderate strength evidence supporting doxepin's efficacy, while evidence for trazodone was insufficient 2.

Efficacy Comparison

Sleep Maintenance (Primary Advantage of Doxepin)

Doxepin demonstrates clinically significant improvements in sleep maintenance parameters 1:

• Wake After Sleep Onset (WASO): Doxepin 3-6 mg produces clinically significant reductions in WASO that exceed threshold criteria, with improvements persisting through all thirds of the night 1
• Total Sleep Time (TST): Both 3 mg and 6 mg doses show clinically significant increases in TST (low-to-moderate strength evidence) 1
• Sleep Efficiency (SE): Both doses exceed clinical significance thresholds for objective sleep efficiency 1

Trazodone 50 mg fails to achieve clinically significant improvements 1:

• WASO reduction of only 7.7 minutes (below clinical threshold) 1
• TST increase of only 21.8 minutes (clinically insignificant) 1
• Sleep quality improvement not statistically significant versus placebo 1
• The AASM concluded that "none of the sleep outcome variables improved to a clinically significant degree" 1

Sleep Onset

For sleep onset latency, neither agent demonstrates strong efficacy 1:

• Doxepin shows minimal improvement in sleep latency, falling below clinical significance thresholds at both 3 mg and 6 mg doses 1
• Trazodone 50 mg reduced sleep latency by only 10.2 minutes, below the clinical significance threshold 1

Next-Day Sedation Profile (Critical Differentiator)

Doxepin: Minimal Residual Effects

Low-dose doxepin (1-6 mg) demonstrates no significant next-day residual effects 1, 3:

• Multiple studies in elderly adults found no memory impairment, no significant next-day residual effects, and side effect profiles comparable to placebo 3
• The AASM guideline specifically noted "minimal evidence of adverse events in excess of placebo" 1
• A 2015 systematic review confirmed "no significant next-day residual effect with low-dose doxepin" 4

Trazodone: Problematic Daytime Sedation

Trazodone is associated with significant next-day somnolence 1:

• 23% of trazodone patients experienced somnolence versus 8% with placebo 1
• 30% reported headache versus 19% with placebo 1
• 75% of trazodone subjects reported some adverse event(s) versus 65.4% with placebo 1

A 2024 comparative study found trazodone had the highest rates of morning grogginess (15%) compared to doxepin (13%) and melatonin (5%) 5.

Safety and Tolerability

Doxepin Safety Profile

Doxepin 3-6 mg shows excellent tolerability 1:

• Adverse effects and study withdrawals did not significantly differ from placebo 2, 1
• Most common side effects: mild increase in somnolence at 6 mg, dry mouth (13%), headache, and diarrhea 1
• No spontaneously reported anticholinergic effects at low doses 3
• FDA labeling notes drowsiness as the most common side effect, which tends to disappear with continued therapy 6

Trazodone Safety Concerns

Trazodone carries more concerning adverse effects 1, 7:

• Higher overall adverse event rate (75% vs 65.4% placebo) 1
• Orthostatic hypotension (10% in recent studies) 5
• Risk of priapism (rare but serious) 7
• The AASM task force judged "harms to potentially outweigh the benefits" given the absence of demonstrated efficacy 1

Recent Comparative Evidence

A 2025 retrospective cohort study directly comparing trazodone 100 mg versus doxepin 25 mg in psychiatric inpatients found no statistically significant difference in treatment failure rates (35.2% vs 41.2%, P=0.58) 8. However, this study used higher doses than guideline-recommended and was in a psychiatric inpatient population, limiting generalizability 8.

A 2024 study in psychiatric patients found trazodone showed the greatest improvement in sleep quality but was associated with frequent adverse effects including morning grogginess (15%) and orthostatic hypotension (10%), while doxepin offered a better balance between effectiveness and tolerability 5.

A 2024 study comparing doxepin 6 mg to zolpidem found doxepin superior for WASO (80.3 vs 132.9 min), TST (378.9 vs 333.2 min), and sleep efficiency (77.8% vs 68.6%), though with higher adverse event rates (23.3% vs 13.3%) 9.

Clinical Algorithm for Selection

Choose low-dose doxepin (3-6 mg) when:

• Sleep maintenance is the primary complaint (difficulty staying asleep, frequent awakenings, early morning awakening) 1
• Minimal next-day sedation is essential (e.g., patients who drive, operate machinery, or need daytime alertness) 1, 4, 3
• Patient is elderly (well-studied and effective in this population) 2, 1, 3
• Long-term treatment is anticipated (better evidence base for sustained efficacy) 1, 4

Start with 3 mg at bedtime; increase to 6 mg if inadequate response after 1-2 weeks 1

Avoid trazodone when:

• Next-day sedation is a concern 1, 5
• Patient has orthostatic hypotension risk 5
• Evidence-based treatment is prioritized (lacks clinically significant efficacy data) 1

Important Caveats

Trazodone's widespread use despite weak evidence: The AASM task force noted that "despite the absence of significant efficacy for trazodone 50 mg and the paucity of information regarding harms, the majority of patients would be likely to use trazodone compared to no treatment" based on its perception as a "safer" sleep-promoting agent by many physicians 1. This perception is not supported by the evidence 1.

Dose considerations: The negative trazodone recommendation is based specifically on 50 mg doses 1. Higher doses (100-150 mg) are commonly used in clinical practice but lack rigorous placebo-controlled trial data for insomnia 8.

Doxepin dosing specificity: The positive evidence and FDA approval for insomnia applies only to low doses (3-6 mg), not the higher antidepressant doses (25-300 mg) 1, 6.

Neither agent excels for sleep onset: If sleep initiation is the primary problem, consider alternative agents like zolpidem, zaleplon, or ramelteon instead 1.